Belzutifan – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 32 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Belzutifan - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Belzutifan is an orally active, small molecule inhibitor of hypoxia-inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Belzutifan is an orally active, small molecule inhibitor of hypoxia-inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindication in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Belzutifan is an orally active, small molecule inhibitor of hypoxia-inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.

Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins. This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired by Merck in 2019). Belzutifan inhibits the complexation of HIF-2α with another transcription factor, HIF-1β, a necessary step in its activation – by preventing the formation of this complex, belzutifan can slow or stop the growth of VHL-associated tumors. Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021.

Mechanism of Action

Hypoxia-inducible factor 2α (HIF-2α) is a transcription factor that aids in oxygen sensing by regulating genes that promote adaptation to hypoxia. In healthy patients, when oxygen levels are normal, HIF-2α is broken down via ubiquitin-proteasomal degradation by von-Hippel Lindau (VHL) proteins. In the presence of hypoxia, HIF-2α translocates into cell nuclei and forms a transcriptional complex with hypoxia-inducible factor 1β (HIF-1β) – this complex then induces the expression of downstream genes associated with cellular proliferation and angiogenesis. Patients with von-Hippel Lindau (VHL) disease lack functional VHL proteins, leading to an accumulation of HIF-2α, and this accumulation is what drives the growth of VHL-associated tumors. Belzutifan is an inhibitor of HIF-2α that prevents its complexation with HIF-1β in conditions of hypoxia or impaired VHL protein function, thereby reducing the expression of HIF-2α target genes and slowing/stopping the growth of VHL-associated tumors.

Belzutifan exerts its therapeutic effects by inhibiting a transcription factor necessary for the growth of solid tumors associated with VHL disease. It is taken once daily at approximately the same time each day, with or without food. Both severe anemia and hypoxia have been observed following therapy with belzutifan, and patients should be monitored closely before and during therapy to ensure patients can be managed as clinically indicated. There are no data regarding the use of erythropoiesis-stimulating agents for the treatment of belzutifan-induced anemia, and as such these therapies should be avoided. Belzutifan may cause embryo-fetal toxicity when administered to pregnant women. Female patients and male patients with female partners of reproductive potential should ensure that an effective form of contraception is used throughout therapy and for one week after the last dose – as belzutifan appears to decrease the efficacy of systemic hormonal contraceptives, patients should be advised to use an additional method of contraception (e.g. condoms) to eliminate the possibility of pregnancy during therapy.

Indications

Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.

  • Cancers linked to Von Hippel-Lindau disease that require treatment but not immediate surgery, including:
  • Central nervous system hemangioblastoma.
  • Pancreatic neuroendocrine tumors
  • Renal cell carcinoma.
  • Hemangioblastoma
  • Pancreatic Neuroendocrine Cancer
  • Renal Cell Carcinoma

Use in Cancer

Belzutifan is approved to treat adults with:

  • Cancers linked to Von Hippel-Lindau disease that require treatment but not immediate surgery, including:
    • Central nervous system hemangioblastoma.
    • Pancreatic neuroendocrine tumors.
    • Renal cell carcinoma.

Belzutifan is also being studied in the treatment of other types of cancer.

Contraindication

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • anemia
  • decreased oxygen in the tissues or blood
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: 40 mg

Von Hippel-Lindau Syndrome

  • 120 mg orally once daily until disease progression or unacceptable toxicity

Renal Dose Adjustments

  • Mild (CrCl 60 to less than 90 mL/min) to moderate (CrCl 30 to less than 60 mL/min) renal dysfunction: No adjustment recommended.
    Severe (CrCl 15 to 30 mL/min) to end-stage renal dysfunction: Data not available

Liver Dose Adjustments

  • Mild (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin upper limit of normal [ULN] or less and aspartate aminotransferase [AST] greater than ULN or total bilirubin greater than 1 to 1.5 x ULN and any AST) hepatic impairment: No adjustment recommended.
    Moderate to severe (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1.5 x ULN and any AST) hepatic impairment: Data not available

Dose Adjustments

Recommended Dose Reductions:

  • First dose reduction: 80 mg orally once daily
  • Second dose reduction: 40 mg orally once daily
  • Third dose reduction: Permanently discontinue therapy.

Dose Modifications for Adverse Reactions:
ANEMIA:

  • Hemoglobin less than 9 g/dL or transfusion indicated: Withhold therapy until hemoglobin 9 g/dL or greater; resume at reduced dose or discontinue depending on the severity of anemia
  • Life-threatening or urgent intervention indicated: Withhold therapy until hemoglobin 9 g/dL or greater; resume at reduced dose or permanently discontinue

HYPOXIA:

  • Decreased oxygen saturation with exercise (e.g., pulse oximeter less than 88%): Consider withholding therapy until resolved; resume at the same dose or at a reduced dose depending on the severity of hypoxia.
  • Decreased oxygen saturation at rest (e.g., pulse oximeter less than 88% or partial pressure of oxygen (PaO2) 55 mm Hg or less) or urgent intervention indicated: Withhold therapy until resolved; resume at reduced dose or discontinue depending on the severity of hypoxia

Side Effects

The Most Common

  • dizziness
  • tiredness
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • nausea
  • constipation
  • stomach pain
  • joint or muscle pain
  • vision changes
  • weight gain
  • fever, cough, shortness of breath, or other signs of infection
  • tiredness, feeling cold, pale skin, shortness of breath, chest pain, or fast heartbeat

More common

  • Body aches or pain
  • chills
  • constipation
  • difficulty in moving
  • ear congestion
  • fever
  • loss of voice
  • muscle aches, cramps, pain, or stiffness
  • nausea
  • pain in the joints
  • sneezing
  • sore throat
  • stomach pain
  • stuffy or runny nose
  • swollen joints
  • weight increased

Rare

  • change in vision
  • chest tightness
  • confusion
  • cough
  • difficulty swallowing
  • dizziness
  • fast heartbeat
  • headache
  • hives, itching, skin rash
  • nervousness
  • pale skin
  • pounding in the ears
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • seeing flashes or sparks of light
  • seeing floating spots before the eyes, or a veil or curtain appearing across part of vision
  • trouble breathing
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

Do not take belzutifan if you are pregnant, plan to become pregnant, or plan to father a child. You will have to take a pregnancy test before starting treatment. If you are female, you will need to use non-hormonal birth control during your treatment and for 1 week after your final dose.

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during therapy with this drug and for 1 week after.

How should this medicine be used?

Belzutifan comes as a tablet to take by mouth. It is usually taken once daily with or without food. Take belzutifan at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take belzutifan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them.

If you vomit after taking belzutifan, do not take another dose. Continue your regular dosing schedule on the next day.

Your doctor may temporarily or permanently stop your treatment or decrease your dose if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with belzutifan. Continue to take belzutifan even if you feel well. Do not stop taking belzutifan without talking to your doctor.

What special precautions should I follow?

Before taking belzutifan,

  • tell your doctor and pharmacist if you are allergic to belzutifan, any other medications, or any of the ingredients in belzutifan tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section any of the following: imatinib (Gleevec), fentanyl (Duragesic), fluvoxamine (Luvox), midazolam, and ticlopidine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with belzutifan, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have or have ever had anemia (a lower-than-normal number of red blood cells).
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking belzutifan and for 1 week after your final dose.
  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of taking belzutifan.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

General physician, urologist, nephrologist, or gynecologist depending on symptoms.

What to tell the doctor

  • Write burning, frequency, fever, flank pain, blood in urine, pregnancy, diabetes, and previous UTI history.

Questions to ask

  • Is this UTI, stone, prostate problem, diabetes-related, or another cause?
  • Do I need urine culture before antibiotics?

Tests to discuss

  • Urine routine/microscopy
  • Urine culture for recurrent/severe infection or treatment failure
  • Blood sugar and kidney function when indicated
  • Ultrasound if stone/obstruction/recurrent symptoms

Avoid these mistakes

  • Avoid self-starting antibiotics; wrong antibiotic can cause resistance.
  • Seek urgent care for fever with flank pain, pregnancy, vomiting, confusion, or inability to pass urine.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Belzutifan – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Hypoxia-inducible factor 2α (HIF-2α) is a transcription factor that aids in oxygen sensing by regulating genes that promote adaptation to hypoxia. In healthy patients, when oxygen levels are normal, HIF-2α is broken down via ubiquitin-proteasomal degradation by von-Hippel Lindau (VHL) proteins. In the presence of hypoxia, HIF-2α translocates into cell nuclei and forms a transcriptional complex with hypoxia-inducible factor 1β (HIF-1β) - this complex then induces the expression of downstream genes associated with cellular proliferation and angiogenesis. Patients with von-Hippel Lindau (VHL) disease lack functional VHL proteins, leading to an accumulation of HIF-2α, and this accumulation is what drives the growth of VHL-associated tumors. Belzutifan is an inhibitor of HIF-2α that prevents its complexation with HIF-1β in conditions of hypoxia or impaired VHL protein function, thereby reducing the expression of HIF-2α target genes and slowing/stopping the growth of VHL-associated tumors. Belzutifan exerts its therapeutic effects by inhibiting a transcription factor necessary for the growth of solid tumors associated with VHL disease. It is taken once daily at approximately the same time each day, with or without food. Both severe anemia and hypoxia have been observed following therapy with belzutifan, and patients should be monitored closely before and during therapy to ensure patients can be managed as clinically indicated. There are no data regarding the use of erythropoiesis-stimulating agents for the treatment of belzutifan-induced anemia, and as such these therapies should be avoided. Belzutifan may cause embryo-fetal toxicity when administered to pregnant women. Female patients and male patients with female partners of reproductive potential should ensure that an effective form of contraception is used throughout therapy and for one week after the last dose - as belzutifan appears to decrease the efficacy of systemic hormonal contraceptives, patients should be advised to use an additional method of contraception (e.g. condoms) to eliminate the possibility of pregnancy during therapy. Indications Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery. Cancers linked to Von Hippel-Lindau disease that require treatment but not immediate surgery, including: Central nervous system hemangioblastoma. Pancreatic neuroendocrine tumors Renal cell carcinoma. Hemangioblastoma Pancreatic Neuroendocrine Cancer Renal Cell Carcinoma Use in Cancer Belzutifan is approved to treat adults with: Cancers linked to Von Hippel-Lindau disease that require treatment but not immediate surgery, including: Central nervous system hemangioblastoma. Pancreatic neuroendocrine tumors. Renal cell carcinoma. Belzutifan is also being studied in the treatment of other types of cancer. Contraindication The following conditions are contraindicated with this drug. Check with your physician if you have any of the following: anemia decreased oxygen in the tissues or blood pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 40 mg Von Hippel-Lindau Syndrome 120 mg orally once daily until disease progression or unacceptable toxicity Renal Dose Adjustments Mild (CrCl 60 to less than 90 mL/min) to moderate (CrCl 30 to less than 60 mL/min) renal dysfunction: No adjustment recommended. Severe (CrCl 15 to 30 mL/min) to end-stage renal dysfunction: Data not available Liver Dose Adjustments Mild (total bilirubin upper limit of normal [ULN] or less and aspartate aminotransferase [AST] greater than ULN or total bilirubin greater than 1 to 1.5 x ULN and any AST) hepatic impairment: No adjustment recommended. Moderate to severe (total bilirubin greater than 1.5 x ULN and any AST) hepatic impairment: Data not available Dose Adjustments Recommended Dose Reductions: First dose reduction: 80 mg orally once daily Second dose reduction: 40 mg orally once daily Third dose reduction: Permanently discontinue therapy. Dose Modifications for Adverse Reactions: ANEMIA: Hemoglobin less than 9 g/dL or transfusion indicated: Withhold therapy until hemoglobin 9 g/dL or greater; resume at reduced dose or discontinue depending on the severity of anemia Life-threatening or urgent intervention indicated: Withhold therapy until hemoglobin 9 g/dL or greater; resume at reduced dose or permanently discontinue HYPOXIA: Decreased oxygen saturation with exercise (e.g., pulse oximeter less than 88%): Consider withholding therapy until resolved; resume at the same dose or at a reduced dose depending on the severity of hypoxia. Decreased oxygen saturation at rest (e.g., pulse oximeter less than 88% or partial pressure of oxygen (PaO2) 55 mm Hg or less) or urgent intervention indicated: Withhold therapy until resolved; resume at reduced dose or discontinue depending on the severity of hypoxia Side Effects The Most Common dizziness tiredness headache nausea constipation stomach pain joint or muscle pain vision changes weight gain fever, cough, shortness of breath, or other signs of infection tiredness, feeling cold, pale skin, shortness of breath, chest pain, or fast heartbeat More common Body aches or pain chills constipation difficulty in moving ear congestion fever loss of voice muscle aches, cramps, pain, or stiffness nausea pain in the joints sneezing sore throat stomach pain stuffy or runny nose swollen joints weight increased Rare change in vision chest tightness confusion cough difficulty swallowing dizziness fast heartbeat headache hives, itching, skin rash nervousness pale skin pounding in the ears puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue seeing flashes or sparks of light seeing floating spots before the eyes, or a veil or curtain appearing across part of vision trouble breathing unusual bleeding or bruising unusual tiredness or weakness Drug Interaction DRUG INTERACTION Abatacept The metabolism of Belzutifan can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with Belzutifan. Abiraterone The serum concentration of Belzutifan can be increased when it is combined with Abiraterone. Abrocitinib The metabolism of Belzutifan can be decreased when combined with Abrocitinib. Acalabrutinib The serum concentration of Acalabrutinib can be decreased when it is combined with Belzutifan. Acenocoumarol The serum concentration of Acenocoumarol can be decreased when it is combined with Belzutifan. Adalimumab The metabolism of Belzutifan can be increased when combined with Adalimumab. Albendazole The metabolism of Belzutifan can be decreased when combined with Albendazole. Alectinib The serum concentration of Alectinib can be decreased when it is combined with Belzutifan. Alpelisib The serum concentration of Alpelisib can be decreased when it is combined with Belzutifan. Aminophenazone The serum concentration of Belzutifan can be increased when it is combined with Aminophenazone. Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Belzutifan. Amiodarone The serum concentration of Amiodarone can be decreased when it is combined with Belzutifan. Amitriptyline The serum concentration of Belzutifan can be increased when it is combined with Amitriptyline. Amprenavir The serum concentration of Belzutifan can be increased when it is combined with Amprenavir. Anakinra The metabolism of Belzutifan can be increased when combined with Anakinra. Antipyrine The serum concentration of Belzutifan can be increased when it is combined with Antipyrine. Apalutamide The serum concentration of Belzutifan can be increased when it is combined with Apalutamide. Apixaban The metabolism of Belzutifan can be decreased when combined with Apixaban. Apremilast The metabolism of Belzutifan can be increased when combined with Apremilast. Aprepitant The serum concentration of Belzutifan can be increased when it is combined with Aprepitant. Armodafinil The serum concentration of Belzutifan can be increased when it is combined with Armodafinil. Artemether The metabolism of Belzutifan can be decreased when combined with Artemether. Artenimol The serum concentration of Belzutifan can be increased when it is combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Articaine. Asciminib The metabolism of Belzutifan can be decreased when combined with Asciminib. Astemizole The serum concentration of Astemizole can be decreased when it is combined with Belzutifan. Axitinib The serum concentration of Axitinib can be decreased when it is combined with Belzutifan. Azelastine The serum concentration of Belzutifan can be increased when it is combined with Azelastine. Benzocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Benzyl alcohol. Bicalutamide The serum concentration of Bicalutamide can be decreased when it is combined with Belzutifan. Bimekizumab The metabolism of Belzutifan can be increased when combined with Bimekizumab. Bortezomib The serum concentration of Bortezomib can be decreased when it is combined with Belzutifan. Bosutinib The serum concentration of Bosutinib can be decreased when it is combined with Belzutifan. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be decreased when it is combined with Belzutifan. Brigatinib The serum concentration of Brigatinib can be decreased when it is combined with Belzutifan. Bupivacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Bupivacaine. Buprenorphine The serum concentration of Belzutifan can be increased when it is combined with Buprenorphine. Busulfan The serum concentration of Busulfan can be decreased when it is combined with Belzutifan. Butacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be decreased when it is combined with Belzutifan. Cabergoline The serum concentration of Cabergoline can be decreased when it is combined with Belzutifan. Canakinumab The metabolism of Belzutifan can be increased when combined with Canakinumab. Cannabidiol The serum concentration of Belzutifan can be increased when it is combined with Cannabidiol. Capsaicin The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Capsaicin. Carbamazepine The serum concentration of Carbamazepine can be decreased when it is combined with Belzutifan. Carisoprodol The metabolism of Belzutifan can be decreased when combined with Carisoprodol. Cenobamate The serum concentration of Belzutifan can be increased when it is combined with Cenobamate. Ceritinib The serum concentration of Ceritinib can be decreased when it is combined with Belzutifan. Certolizumab pegol The metabolism of Belzutifan can be increased when combined with Certolizumab pegol. Chloramphenicol The serum concentration of Belzutifan can be increased when it is combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Chloroprocaine. Cimetidine The serum concentration of Belzutifan can be increased when it is combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Cinchocaine. Citalopram The serum concentration of Belzutifan can be increased when it is combined with Citalopram. Clevidipine The serum concentration of Belzutifan can be increased when it is combined with Clevidipine. Clobazam The metabolism of Belzutifan can be decreased when combined with Clobazam. Clomipramine The serum concentration of Clomipramine can be decreased when it is combined with Belzutifan. Clonidine The serum concentration of Clonidine can be decreased when it is combined with Belzutifan. Clopidogrel The metabolism of Belzutifan can be decreased when combined with Clopidogrel. Clozapine The serum concentration of Belzutifan can be increased when it is combined with Clozapine. Cobimetinib The serum concentration of Cobimetinib can be decreased when it is combined with Belzutifan. Cocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Cocaine. Conivaptan The serum concentration of Conivaptan can be decreased when it is combined with Belzutifan. Copanlisib The serum concentration of Copanlisib can be decreased when it is combined with Belzutifan. Crizotinib The serum concentration of Crizotinib can be decreased when it is combined with Belzutifan. Cyclophosphamide The serum concentration of Cyclophosphamide can be decreased when it is combined with Belzutifan. Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Belzutifan. Cyproterone acetate The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Belzutifan. Dabrafenib The serum concentration of Dabrafenib can be decreased when it is combined with Belzutifan. Dacomitinib The serum concentration of Dacomitinib can be decreased when it is combined with Belzutifan. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belzutifan. Dasatinib The serum concentration of Dasatinib can be decreased when it is combined with Belzutifan. Delavirdine The serum concentration of Belzutifan can be increased when it is combined with Delavirdine. Desogestrel The therapeutic efficacy of Desogestrel can be decreased when used in combination with Belzutifan. Dexlansoprazole The metabolism of Belzutifan can be decreased when combined with Dexlansoprazole. Diazepam The serum concentration of Belzutifan can be increased when it is combined with Diazepam. Dienogest The therapeutic efficacy of Dienogest can be decreased when used in combination with Belzutifan. Diethylstilbestrol The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Belzutifan. Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Belzutifan. Dihydroergotamine The serum concentration of Dihydroergotamine can be decreased when it is combined with Belzutifan. Dimethyl sulfoxide The serum concentration of Belzutifan can be increased when it is combined with Dimethyl sulfoxide. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Diphenhydramine. Docetaxel The serum concentration of Docetaxel can be decreased when it is combined with Belzutifan. Dofetilide The serum concentration of Dofetilide can be decreased when it is combined with Belzutifan. Dosulepin The serum concentration of Belzutifan can be increased when it is combined with Dosulepin. Doxazosin The metabolism of Belzutifan can be decreased when combined with Doxazosin. Doxepin The metabolism of Belzutifan can be decreased when combined with Doxepin. Doxorubicin The serum concentration of Doxorubicin can be decreased when it is combined with Belzutifan. Dronabinol The metabolism of Belzutifan can be decreased when combined with Dronabinol. Dronedarone The serum concentration of Dronedarone can be decreased when it is combined with Belzutifan. Drospirenone The therapeutic efficacy of Drospirenone can be decreased when used in combination with Belzutifan. Dyclonine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Dyclonine. Efavirenz The serum concentration of Belzutifan can be increased when it is combined with Efavirenz. Elagolix The serum concentration of Belzutifan can be increased when it is combined with Elagolix. Emapalumab The metabolism of Belzutifan can be increased when combined with Emapalumab. Enasidenib The serum concentration of Enasidenib can be decreased when it is combined with Belzutifan. Entrectinib The serum concentration of Entrectinib can be decreased when it is combined with Belzutifan. Enzalutamide The serum concentration of Belzutifan can be decreased when it is combined with Enzalutamide. Erdafitinib The serum concentration of Erdafitinib can be decreased when it is combined with Belzutifan. Ergotamine The serum concentration of Ergotamine can be decreased when it is combined with Belzutifan. Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Belzutifan. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Belzutifan. Escitalopram The metabolism of Belzutifan can be decreased when combined with Escitalopram. Esketamine The metabolism of Belzutifan can be decreased when combined with Esketamine. Eslicarbazepine The serum concentration of Belzutifan can be increased when it is combined with Eslicarbazepine. Eslicarbazepine acetate The serum concentration of Belzutifan can be increased when it is combined with Eslicarbazepine acetate. Esomeprazole The serum concentration of Belzutifan can be increased when it is combined with Esomeprazole. Estradiol The therapeutic efficacy of Estradiol can be decreased when used in combination with Belzutifan. Estradiol benzoate The therapeutic efficacy of Estradiol benzoate can be decreased when used in combination with Belzutifan. Estradiol cypionate The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Belzutifan. Estradiol valerate The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Belzutifan. Estrone sulfate The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Belzutifan. Etanercept The metabolism of Belzutifan can be increased when combined with Etanercept. Ethambutol The metabolism of Belzutifan can be decreased when combined with Ethambutol. Ethanol The serum concentration of Belzutifan can be increased when it is combined with Ethanol. Ethinylestradiol The serum concentration of Belzutifan can be increased when it is combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Ethyl chloride. Ethynodiol diacetate The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Belzutifan. Etidocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Etidocaine. Etonogestrel The therapeutic efficacy of Etonogestrel can be decreased when used in combination with Belzutifan. Etoposide The serum concentration of Etoposide can be decreased when it is combined with Belzutifan. Etoricoxib The serum concentration of Belzutifan can be increased when it is combined with Etoricoxib. Etravirine The serum concentration of Belzutifan can be increased when it is combined with Etravirine. Everolimus The serum concentration of Everolimus can be decreased when it is combined with Belzutifan. Fedratinib The metabolism of Belzutifan can be decreased when combined with Fedratinib. Felbamate The serum concentration of Belzutifan can be increased when it is combined with Felbamate. Fenofibrate The serum concentration of Belzutifan can be increased when it is combined with Fenofibrate. Fexinidazole The serum concentration of Belzutifan can be increased when it is combined with Fexinidazole. Fluconazole The serum concentration of Belzutifan can be increased when it is combined with Fluconazole. Fluoxetine The serum concentration of Belzutifan can be increased when it is combined with Fluoxetine. Fluvastatin The serum concentration of Belzutifan can be increased when it is combined with Fluvastatin. Fluvoxamine The serum concentration of Belzutifan can be increased when it is combined with Fluvoxamine. Formoterol The metabolism of Belzutifan can be decreased when combined with Formoterol. Fosphenytoin The serum concentration of Fosphenytoin can be decreased when it is combined with Belzutifan. Gemfibrozil The serum concentration of Belzutifan can be increased when it is combined with Gemfibrozil. Gestrinone The therapeutic efficacy of Gestrinone can be decreased when used in combination with Belzutifan. Gliclazide The metabolism of Belzutifan can be decreased when combined with Gliclazide. Glyburide The metabolism of Belzutifan can be decreased when combined with Glyburide. Golimumab The metabolism of Belzutifan can be increased when combined with Golimumab. Hydroxyprogesterone The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Belzutifan. Idelalisib The serum concentration of Idelalisib can be decreased when it is combined with Belzutifan. Ifosfamide The serum concentration of Ifosfamide can be decreased when it is combined with Belzutifan. Imatinib The metabolism of Belzutifan can be decreased when combined with Imatinib. Imipramine The serum concentration of Belzutifan can be increased when it is combined with Imipramine. Indomethacin The serum concentration of Belzutifan can be increased when it is combined with Indomethacin. Infliximab The metabolism of Belzutifan can be increased when combined with Infliximab. Irinotecan The serum concentration of Irinotecan can be decreased when it is combined with Belzutifan. Isavuconazole The serum concentration of Belzutifan can be increased when it is combined with Isavuconazole. Isoniazid The serum concentration of Belzutifan can be increased when it is combined with Isoniazid. Ivosidenib The serum concentration of Ivosidenib can be decreased when it is combined with Belzutifan. Ixabepilone The serum concentration of Ixabepilone can be decreased when it is combined with Belzutifan. Ixazomib The serum concentration of Ixazomib can be decreased when it is combined with Belzutifan. Ketoconazole The serum concentration of Belzutifan can be increased when it is combined with Ketoconazole. Labetalol The metabolism of Belzutifan can be decreased when combined with Labetalol. Lacosamide The metabolism of Belzutifan can be decreased when combined with Lacosamide. Lansoprazole The serum concentration of Belzutifan can be increased when it is combined with Lansoprazole. Lapatinib The metabolism of Belzutifan can be decreased when combined with Lapatinib. Letermovir The metabolism of Belzutifan can be increased when combined with Letermovir. Letrozole The serum concentration of Belzutifan can be increased when it is combined with Letrozole. Levacetylmethadol The serum concentration of Levacetylmethadol can be decreased when it is combined with Belzutifan. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Levobupivacaine. Levonorgestrel The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Belzutifan. Lidocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Lidocaine. Lomitapide The serum concentration of Lomitapide can be decreased when it is combined with Belzutifan. Lonafarnib The serum concentration of Belzutifan can be increased when it is combined with Lonafarnib. Losartan The serum concentration of Belzutifan can be increased when it is combined with Losartan. Luliconazole The serum concentration of Belzutifan can be increased when it is combined with Luliconazole. Lumacaftor The serum concentration of Belzutifan can be decreased when it is combined with Lumacaftor. Lynestrenol The serum concentration of Belzutifan can be increased when it is combined with Lynestrenol. Manidipine The serum concentration of Belzutifan can be increased when it is combined with Manidipine. Mavacamten The serum concentration of Belzutifan can be decreased when it is combined with Mavacamten. Medroxyprogesterone The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Belzutifan. Megestrol acetate The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Belzutifan. Meloxicam The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Meloxicam. Memantine The serum concentration of Belzutifan can be increased when it is combined with Memantine. Mephenytoin The serum concentration of Belzutifan can be increased when it is combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Mepivacaine. Mestranol The therapeutic efficacy of Mestranol can be decreased when used in combination with Belzutifan. Methadone The metabolism of Belzutifan can be decreased when combined with Methadone. Methimazole The serum concentration of Belzutifan can be increased when it is combined with Methimazole. Methotrexate The serum concentration of Methotrexate can be decreased when it is combined with Belzutifan. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belzutifan. Methsuximide The serum concentration of Belzutifan can be increased when it is combined with Methsuximide. Methylene blue The serum concentration of Belzutifan can be increased when it is combined with Methylene blue. Methylphenobarbital The metabolism of Belzutifan can be decreased when combined with Methylphenobarbital. Miconazole The serum concentration of Belzutifan can be increased when it is combined with Miconazole. Midostaurin The serum concentration of Midostaurin can be decreased when it is combined with Belzutifan. Mifepristone The therapeutic efficacy of Mifepristone can be decreased when used in combination with Belzutifan. Moclobemide The serum concentration of Belzutifan can be increased when it is combined with Moclobemide. Modafinil The serum concentration of Belzutifan can be increased when it is combined with Modafinil. Nebivolol The metabolism of Belzutifan can be decreased when combined with Nebivolol. Neratinib The serum concentration of Neratinib can be decreased when it is combined with Belzutifan. Nicardipine The serum concentration of Belzutifan can be increased when it is combined with Nicardipine. Nilotinib The serum concentration of Nilotinib can be decreased when it is combined with Belzutifan. Nilutamide The serum concentration of Belzutifan can be increased when it is combined with Nilutamide. Nilvadipine The serum concentration of Belzutifan can be increased when it is combined with Nilvadipine. Nomegestrol The therapeutic efficacy of Nomegestrol can be decreased when used in combination with Belzutifan. Norethisterone The therapeutic efficacy of Norethisterone can be decreased when used in combination with Belzutifan. Norethynodrel The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Belzutifan. Norgestimate The therapeutic efficacy of Norgestimate can be decreased when used in combination with Belzutifan. Norgestrel The therapeutic efficacy of Norgestrel can be decreased when used in combination with Belzutifan. Nortriptyline The serum concentration of Nortriptyline can be decreased when it is combined with Belzutifan. Olanzapine The serum concentration of Belzutifan can be increased when it is combined with Olanzapine. Olaparib The serum concentration of Olaparib can be decreased when it is combined with Belzutifan. Omeprazole The serum concentration of Belzutifan can be increased when it is combined with Omeprazole. Oritavancin The serum concentration of Belzutifan can be increased when it is combined with Oritavancin. Osilodrostat The serum concentration of Belzutifan can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Osimertinib can be decreased when it is combined with Belzutifan. Oxcarbazepine The serum concentration of Belzutifan can be increased when it is combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Oxybuprocaine. Paclitaxel The serum concentration of Paclitaxel can be decreased when it is combined with Belzutifan. Palbociclib The serum concentration of Palbociclib can be decreased when it is combined with Belzutifan. Panobinostat The serum concentration of Panobinostat can be decreased when it is combined with Belzutifan. Pantoprazole The serum concentration of Belzutifan can be increased when it is combined with Pantoprazole. Paroxetine The metabolism of Belzutifan can be decreased when combined with Paroxetine. Pazopanib The serum concentration of Pazopanib can be decreased when it is combined with Belzutifan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Belzutifan. Pentamidine The metabolism of Belzutifan can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Belzutifan can be decreased when combined with Pentobarbital. Pexidartinib The serum concentration of Pexidartinib can be decreased when it is combined with Belzutifan. Phenelzine The serum concentration of Belzutifan can be increased when it is combined with Phenelzine. Phenobarbital The metabolism of Belzutifan can be decreased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Phenol. Phenprocoumon The serum concentration of Phenprocoumon can be decreased when it is combined with Belzutifan. Phenytoin The metabolism of Belzutifan can be increased when combined with Phenytoin. Pimozide The serum concentration of Pimozide can be decreased when it is combined with Belzutifan. Piperaquine The serum concentration of Belzutifan can be increased when it is combined with Piperaquine. Pirfenidone The metabolism of Belzutifan can be decreased when combined with Pirfenidone. Pomalidomide The serum concentration of Pomalidomide can be decreased when it is combined with Belzutifan. Ponatinib The serum concentration of Ponatinib can be decreased when it is combined with Belzutifan. Pramocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Pramocaine. Praziquantel The metabolism of Belzutifan can be decreased when combined with Praziquantel. Prilocaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Prilocaine. Primidone The metabolism of Belzutifan can be decreased when combined with Primidone. Probenecid The serum concentration of Belzutifan can be increased when it is combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Procaine. Progesterone The serum concentration of Belzutifan can be increased when it is combined with Progesterone. Proguanil The metabolism of Belzutifan can be decreased when combined with Proguanil. Proparacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Propoxycaine. Propranolol The metabolism of Belzutifan can be decreased when combined with Propranolol. Quinidine The serum concentration of Quinidine can be decreased when it is combined with Belzutifan. Quinine The serum concentration of Belzutifan can be increased when it is combined with Quinine. Rabeprazole The serum concentration of Belzutifan can be increased when it is combined with Rabeprazole. Ramelteon The metabolism of Belzutifan can be decreased when combined with Ramelteon. Regorafenib The serum concentration of Regorafenib can be decreased when it is combined with Belzutifan. Ribociclib The serum concentration of Ribociclib can be decreased when it is combined with Belzutifan. Rifabutin The metabolism of Belzutifan can be increased when combined with Rifabutin. Rifampicin The metabolism of Belzutifan can be increased when combined with Rifampicin. Rifamycin The serum concentration of Belzutifan can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Belzutifan can be increased when combined with Rifapentine. Rilonacept The metabolism of Belzutifan can be increased when combined with Rilonacept. Rilpivirine The metabolism of Belzutifan can be decreased when combined with Rilpivirine. Ritonavir The serum concentration of Belzutifan can be increased when it is combined with Ritonavir. Romidepsin The serum concentration of Romidepsin can be decreased when it is combined with Belzutifan. Ropivacaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Ropivacaine. Rucaparib The serum concentration of Belzutifan can be increased when it is combined with Rucaparib. Ruxolitinib The serum concentration of Ruxolitinib can be decreased when it is combined with Belzutifan. Safinamide The serum concentration of Belzutifan can be increased when it is combined with Safinamide. Natalizumab The serum concentration of Belzutifan can be decreased when it is combined with Satralizumab. Secukinumab The metabolism of Belzutifan can be increased when combined with Secukinumab. Progesterone acetate The therapeutic efficacy of Segesterone acetate can be decreased when used in combination with Belzutifan. Selumetinib The metabolism of Belzutifan can be decreased when combined with Selumetinib. Sertraline The serum concentration of Belzutifan can be increased when it is combined with Sertraline. Sildenafil The serum concentration of Belzutifan can be increased when it is combined with Sildenafil. Siltuximab The metabolism of Belzutifan can be increased when combined with Siltuximab. Siponimod The serum concentration of Siponimod can be decreased when it is combined with Belzutifan. Sirolimus The serum concentration of Sirolimus can be decreased when it is combined with Belzutifan. Sitaxentan The serum concentration of Belzutifan can be increased when it is combined with Sitaxentan. Somapacitan The serum concentration of Belzutifan can be increased when it is combined with Somapacitan. Somatotropin The serum concentration of Belzutifan can be increased when it is combined with Somatotropin. Sonidegib The serum concentration of Sonidegib can be decreased when it is combined with Belzutifan. Sorafenib The serum concentration of Sorafenib can be decreased when it is combined with Belzutifan. St. John's Wort The metabolism of Belzutifan can be decreased when combined with St. John's Wort. Stiripentol The serum concentration of Belzutifan can be increased when it is combined with Stiripentol. Sulfanilamide The serum concentration of Belzutifan can be increased when it is combined with Sulfanilamide. Sunitinib The serum concentration of Sunitinib can be decreased when it is combined with Belzutifan. Tacrolimus The serum concentration of Tacrolimus can be decreased when it is combined with Belzutifan. Tamoxifen The serum concentration of Tamoxifen can be decreased when it is combined with Belzutifan. Tecovirimat The metabolism of Belzutifan can be decreased when combined with Tecovirimat. Telmisartan The serum concentration of Belzutifan can be increased when it is combined with Telmisartan. Temsirolimus The serum concentration of Temsirolimus can be decreased when it is combined with Belzutifan. Teniposide The serum concentration of Teniposide can be decreased when it is combined with Belzutifan. Testosterone The metabolism of Belzutifan can be decreased when combined with Testosterone. Testosterone The therapeutic efficacy of Testosterone enanthate can be decreased when used in combination with Belzutifan. Tetracaine The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Tetracaine. Thalidomide The serum concentration of Belzutifan can be increased when it is combined with Thalidomide. Theophylline The serum concentration of Theophylline can be decreased when it is combined with Belzutifan. Thiopental The metabolism of Belzutifan can be decreased when combined with Thiopental. Thioridazine The metabolism of Belzutifan can be decreased when combined with Thioridazine. Thiotepa The serum concentration of Thiotepa can be decreased when it is combined with Belzutifan. Ticlopidine The serum concentration of Belzutifan can be increased when it is combined with Ticlopidine. Timolol The metabolism of Belzutifan can be decreased when combined with Timolol. Tioconazole The serum concentration of Belzutifan can be increased when it is combined with Tioconazole. Tipranavir The serum concentration of Belzutifan can be increased when it is combined with Tipranavir. Tocilizumab The metabolism of Belzutifan can be increased when combined with Tocilizumab. Tolvaptan The serum concentration of Tolvaptan can be decreased when it is combined with Belzutifan. Topiramate The serum concentration of Belzutifan can be increased when it is combined with Topiramate. Trabectedin The serum concentration of Trabectedin can be decreased when it is combined with Belzutifan. Tranylcypromine The serum concentration of Belzutifan can be increased when it is combined with Tranylcypromine. Trastuzumab The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Belzutifan. Triclabendazole The metabolism of Belzutifan can be decreased when combined with Triclabendazole. Trimethadione The metabolism of Belzutifan can be decreased when combined with Trimethadione. Ulipristal The therapeutic efficacy of Ulipristal can be decreased when used in combination with Belzutifan. Valproic acid The serum concentration of Belzutifan can be increased when it is combined with Valproic acid. Vandetanib The serum concentration of Vandetanib can be decreased when it is combined with Belzutifan. Vemurafenib The serum concentration of Vemurafenib can be decreased when it is combined with Belzutifan. Venetoclax The serum concentration of Venetoclax can be decreased when it is combined with Belzutifan. Verapamil The metabolism of Belzutifan can be decreased when combined with Verapamil. Vilazodone The metabolism of Belzutifan can be decreased when combined with Vilazodone. Vinblastine The serum concentration of Vinblastine can be decreased when it is combined with Belzutifan. Vincristine The serum concentration of Vincristine can be decreased when it is combined with Belzutifan. Vindesine The serum concentration of Vindesine can be decreased when it is combined with Belzutifan. Vinflunine The serum concentration of Vinflunine can be decreased when it is combined with Belzutifan. Vinorelbine The serum concentration of Vinorelbine can be decreased when it is combined with Belzutifan. Vismodegib The serum concentration of Belzutifan can be increased when it is combined with Vismodegib. Vonoprazan The serum concentration of Belzutifan can be increased when it is combined with Vonoprazan. Voriconazole The serum concentration of Belzutifan can be increased when it is combined with Voriconazole. Vortioxetine The metabolism of Belzutifan can be decreased when combined with Vortioxetine. Voxelotor The metabolism of Belzutifan can be decreased when combined with Voxelotor. Warfarin The serum concentration of Warfarin can be decreased when it is combined with Belzutifan. Zafirlukast The serum concentration of Belzutifan can be increased when it is combined with Zafirlukast. Zanubrutinib The serum concentration of Zanubrutinib can be decreased when it is combined with Belzutifan. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy Do not take belzutifan if you are pregnant, plan to become pregnant, or plan to father a child. You will have to take a pregnancy test before starting treatment. If you are female, you will need to use non-hormonal birth control during your treatment and for 1 week after your final dose. Lactation Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during therapy with this drug and for 1 week after. How should this medicine be used?

Belzutifan comes as a tablet to take by mouth. It is usually taken once daily with or without food. Take belzutifan at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take belzutifan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the tablets whole; do not split,…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)